Home › Funds › Affinity Asset Advisors, LLC › PTGX

Affinity Asset Advisors, LLC position in PTGX

PROTAGONIST THERAPEUTICS INC · Health Care

Affinity Asset Advisors, LLC reported holding 172,125 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$24.3M, representing 1.13% of its reported portfolio and ranking #27 among its reported holdings. Affinity Asset Advisors, LLC has disclosed PTGX holdings in 9 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)172.12K sh
Reported value held$24.25M
Portfolio Weight1.13%
First reportedQ1 2024
Last changeHold
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Affinity Asset Advisors, LLC's PTGX position evolved

Affinity Asset Advisors, LLC first disclosed a stake in PTGX in Q1 2024 at 100,000 shares (US$2.9M). The position peaked in Q2 2025 at 440,000 shares, worth US$24.3M. Across 9 filings, Affinity Asset Advisors, LLC increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 172,125 shares valued at US$24.3M. Notable position changes include a 33% increase in Q1 2025 (shares rose 14% over the following quarter), a 155% increase in Q2 2025 (shares rose 20% over the following quarter), a 50% trim in Q3 2025 (shares rose 31% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 100.00K $2.89M New
Q4 2024 130.00K $5.02M New
Q1 2025 172.50K $8.34M Add
Q2 2025 440.00K $24.32M Add
Q3 2025 220.60K $14.65M Reduce
Q4 2025 172.12K $15.03M Reduce
Q1 2026 172.12K $18.14M Hold
Q2 2026 172.12K $21.10M Hold
Q3 2026 172.12K $24.25M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PTGX and 13F data

PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 50 other funds we track also report a position in PTGX — the largest reported positions include Farallon Capital Management (US$778.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$778.2M), RTW INVESTMENTS, LP (US$620.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PTGX

All PTGX fund holders →

FAQ

How long has Affinity Asset Advisors, LLC held PTGX?

Affinity Asset Advisors, LLC has disclosed PTGX holdings in 9 of the last 11 reported quarters, going back to Q1 2024.

What is Affinity Asset Advisors, LLC's current position in PTGX?

As of Q3 2026, Affinity Asset Advisors, LLC holds 172.12K shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $24.25M, representing 1.13% of its reported portfolio and ranking #27.

Has Affinity Asset Advisors, LLC been buying or selling PTGX?

In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC held unchanged its position in PTGX. The position peaked in Q2 2025 at 440.00K shares.

Which other funds hold PTGX?

Other major institutional holders of PTGX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, among 50 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.